You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOfloxacin
Accession NumberDB01165  (APRD00502)
TypeSmall Molecule
GroupsApproved
DescriptionA synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. [PubChem]
Structure
Thumb
Synonyms
8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid
Ofloxacine
Ofloxacino
Ofloxacinum
OFLX
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Floxin I.V. Liq 20mg/mlLiquid20 mgIntravenousOrtho Pharmaceutical, Division Of Janssen Ortho Inc.Not applicableNot applicableCanada
Floxin Tablets 200mgTablet200 mgOralJanssen Inc1992-12-312002-07-31Canada
Floxin Tablets 300mgTablet300 mgOralJanssen Inc1990-12-312006-12-21Canada
Floxin Tablets 400mgTablet400 mgOralJanssen Inc1990-12-312007-01-10Canada
Novo-ofloxacinTablet300 mgOralNovopharm Limited2004-06-112012-05-08Canada
Novo-ofloxacinTablet400 mgOralNovopharm Limited2004-06-112012-05-08Canada
Novo-ofloxacinTablet200 mgOralNovopharm Limited2004-06-112012-05-08Canada
OcufloxSolution / drops3 mg/mLOphthalmicAllergan, Inc.1993-08-01Not applicableUs
OcufloxSolution0.3 %OphthalmicAllergan Inc1995-12-31Not applicableCanada
Ofloxacin TabletsTablet300 mgOralAa Pharma Inc1998-02-042016-08-02Canada
Ofloxacin TabletsTablet400 mgOralAa Pharma Inc1998-02-172016-08-02Canada
Ofloxacin TabletsTablet200 mgOralAa Pharma Inc1998-02-042016-08-02Canada
PMS-ofloxacinSolution0.3 %OphthalmicPharmascience Inc2004-05-202016-10-28Canada
Sandoz OfloxacinSolution0.3 %OphthalmicSandoz Canada Incorporated2012-07-24Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-ofloxacinSolution0.3 %OphthalmicApotex Inc2004-01-22Not applicableCanada
Floxin OticSolution / drops3 mg/mLAuricular (otic)ALMATICA PHARMA INC.2016-07-25Not applicableUs
OfloxacinSolution3 mg/mLAuricular (otic)Aidarex Pharmaceuticals LLC2008-03-17Not applicableUs
OfloxacinSolution3 mg/mLOphthalmicH.J. Harkins Company, Inc.2010-01-04Not applicableUs
OfloxacinSolution / drops3 mg/mLOphthalmicDIRECT RX2014-01-01Not applicableUs
OfloxacinSolution3 mg/mLAuricular (otic)DIRECT RX2014-01-01Not applicableUs
OfloxacinSolution / drops3 mg/mLOphthalmicHenry Schein Inc.2015-05-13Not applicableUs
OfloxacinSolution3 mg/mLOphthalmicREMEDYREPACK INC.2013-06-13Not applicableUs
OfloxacinSolution3 mg/mLAuricular (otic)Lake Erie Medical DBA Quality Care Products LLC2008-03-31Not applicableUs
OfloxacinSolution3 mg/mLOphthalmicPreferred Pharmaceuticals Inc.2016-02-15Not applicableUs
OfloxacinSolution / drops3 mg/mLOphthalmicA S Medication Solutions2004-05-14Not applicableUs
OfloxacinSolution3 mg/mLOphthalmicRising Pharmaceuticals, Inc.2014-12-15Not applicableUs
OfloxacinTablet, film coated400 mg/1OralLarken Laboratories, Inc.2014-05-20Not applicableUs
OfloxacinSolution / drops3 mg/mLOphthalmicHi Tech Pharmacal Co., Inc.2004-05-14Not applicableUs
OfloxacinTablet, coated300 mg/1OralDr. Reddy's Laboratories Limited2006-02-10Not applicableUs
OfloxacinSolution3 mg/mLOphthalmicFalcon Pharmaceuticals, Ltd.2004-05-14Not applicableUs
OfloxacinSolution / drops3 mg/mLOphthalmicAkorn, Inc.2008-07-01Not applicableUs
OfloxacinTablet, coated400 mg/1OralNivagen Pharmaceuticals, Inc.2016-07-15Not applicableUs
OfloxacinSolution / drops3 mg/mLAuricular (otic)STAT Rx USA LLC2008-03-17Not applicableUs
OfloxacinSolution3 mg/mLAuricular (otic)REMEDYREPACK INC.2013-10-04Not applicableUs
OfloxacinSolution3 mg/mLAuricular (otic)Pharma Force, Inc.2010-01-21Not applicableUs
OfloxacinSolution / drops3 mg/mLAuricular (otic)Physicians Total Care, Inc.2009-05-21Not applicableUs
OfloxacinTablet, film coated200 mg/1OralCadila Pharmaceuticals Limited2014-09-24Not applicableUs
OfloxacinSolution / drops3 mg/mLOphthalmicAmerican Regent, Inc.2010-07-01Not applicableUs
OfloxacinSolution3 mg/mLAuricular (otic)REMEDYREPACK INC.2013-06-13Not applicableUs
OfloxacinSolution3 mg/mLAuricular (otic)Clinical Solutions Wholesale2008-03-172016-10-13Us
OfloxacinSolution3 mg/mLOphthalmicREMEDYREPACK INC.2016-03-02Not applicableUs
OfloxacinSolution / drops3 mg/mLOphthalmicKeltman Pharmaceuticals Inc.2010-01-15Not applicableUs
OfloxacinSolution / drops3 mg/mLOphthalmicA S Medication Solutions2008-07-01Not applicableUs
OfloxacinSolution / drops3 mg/mLAuricular (otic)Hi Tech Pharmacal Co., Inc.2008-03-17Not applicableUs
OfloxacinTablet, coated400 mg/1OralDr. Reddy's Laboratories Limited2006-02-10Not applicableUs
OfloxacinSolution3 mg/mLAuricular (otic)Falcon Pharmaceuticals, Ltd.2008-03-31Not applicableUs
OfloxacinSolution3 mg/mLAuricular (otic)Bausch & Lomb Incorporated2008-03-17Not applicableUs
OfloxacinTablet, coated300 mg/1OralNivagen Pharmaceuticals, Inc.2016-07-15Not applicableUs
OfloxacinSolution / drops3 mg/mLOphthalmicRebel Distributors Corp2004-05-14Not applicableUs
OfloxacinSolution / drops3 mg/mLOphthalmicREMEDYREPACK INC.2014-05-14Not applicableUs
OfloxacinSolution / drops3 mg/mLAuricular (otic)Preferred Pharmaceuticals, Inc.2013-03-22Not applicableUs
OfloxacinSolution3 mg/mLAuricular (otic)Rebel Distributors Corp2008-03-17Not applicableUs
OfloxacinSolution / drops3 mg/mLOphthalmicPhysicians Total Care, Inc.2010-04-20Not applicableUs
OfloxacinSolution / drops3 mg/mLOphthalmicProficient Rx LP2004-05-14Not applicableUs
OfloxacinTablet, film coated300 mg/1OralCadila Pharmaceuticals Limited2014-09-24Not applicableUs
OfloxacinSolution3 mg/mLOphthalmicREMEDYREPACK INC.2016-10-11Not applicableUs
OfloxacinSolution / drops3 mg/mLOphthalmicMwi2015-03-27Not applicableUs
OfloxacinSolution3 mg/mLOphthalmicREMEDYREPACK INC.2013-11-252016-04-05Us
OfloxacinSolution / drops3 mg/mLOphthalmicClinical Solutions Wholesale2004-05-142016-10-13Us
OfloxacinSolution / drops3 mg/mLOphthalmicProficient Rx LP2008-07-01Not applicableUs
OfloxacinSolution3 mg/mLOphthalmicFdc Limited2014-12-15Not applicableUs
OfloxacinSolution3 mg/mLAuricular (otic)A S Medication Solutions2008-03-31Not applicableUs
OfloxacinSolution / drops3 mg/mLOphthalmicUnit Dose Services2004-05-14Not applicableUs
OfloxacinSolution / drops3 mg/mLAuricular (otic)Rebel Distributors Corp2008-03-17Not applicableUs
OfloxacinSolution / drops3 mg/mLOphthalmicREMEDYREPACK INC.2014-02-26Not applicableUs
OfloxacinSolution / drops3 mg/mLOphthalmicBausch & Lomb Incorporated2004-05-14Not applicableUs
OfloxacinTablet, coated200 mg/1OralNivagen Pharmaceuticals, Inc.2016-07-15Not applicableUs
OfloxacinSolution / drops3 mg/mLOphthalmicPreferred Pharmaceuticals, Inc.2013-05-14Not applicableUs
OfloxacinTablet, film coated400 mg/1OralPd Rx Pharmaceuticals, Inc.2004-01-28Not applicableUs
OfloxacinTablet, coated200 mg/1OralDr. Reddy's Laboratories Limited2006-02-10Not applicableUs
OfloxacinSolution3 mg/mLAuricular (otic)Proficient Rx LP2008-03-17Not applicableUs
OfloxacinTablet, film coated400 mg/1OralCadila Pharmaceuticals Limited2014-09-24Not applicableUs
OfloxacinSolution3 mg/mLOphthalmicREMEDYREPACK INC.2016-04-11Not applicableUs
OfloxacinSolution3 mg/mLOphthalmicProficient Rx LP2014-12-15Not applicableUs
OfloxacinSolution / drops3 mg/mLOphthalmicSTAT RX LLC USA2004-05-14Not applicableUs
OfloxacinSolution3 mg/mLOphthalmicREMEDYREPACK INC.2013-07-01Not applicableUs
OfloxacinTablet, film coated200 mg/1OralREMEDYREPACK INC.2013-03-27Not applicableUs
OfloxacinSolution / drops3 mg/mLOphthalmicLake Erie Medical DBA Quality Care Products LLC2008-07-01Not applicableUs
OfloxacinSolution3 mg/mLAuricular (otic)Lake Erie Medical DBA Quality Care Products LLC2008-03-17Not applicableUs
OfloxacinSolution3 mg/mLAuricular (otic)A S Medication Solutions2008-03-17Not applicableUs
Ofloxacin OphthalmicSolution3 mg/mLOphthalmicAltaire Pharmaceuticals Inc.2013-05-31Not applicableUs
Ofloxacin OticSolution3 mg/mLAuricular (otic)Apotex Corp.2004-05-14Not applicableUs
Ofloxacin OticSolution3 mg/mLAuricular (otic)Preferred Pharmaceuticals, Inc.2014-02-21Not applicableUs
Ofloxacin OticSolution3 mg/mLAuricular (otic)Proficient Rx LP2004-05-14Not applicableUs
Ofloxacin OticSolution3 mg/mLAuricular (otic)REMEDYREPACK INC.2014-09-30Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
FloxinNot Available
FloxstatNot Available
ZanocinNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIA4P49JAZ9H
CAS number82419-36-1
WeightAverage: 361.3675
Monoisotopic: 361.143784348
Chemical FormulaC18H20FN3O4
InChI KeyGSDSWSVVBLHKDQ-UHFFFAOYSA-N
InChI
InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)
IUPAC Name
7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0⁵,¹³]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
SMILES
CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1
Pharmacology
IndicationFor the treatment of infections (respiratory tract, kidney, skin, soft tissue, UTI), urethral and cervical gonorrhoea.
Structured Indications
PharmacodynamicsOfloxacin is a quinolone/fluoroquinolone antibiotic. Ofloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. Ofloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria.
Mechanism of actionOfloxacin acts on DNA gyrase and toposiomerase IV, enzymes which, like human topoisomerase, prevents the excessive supercoiling of DNA during replication or transcription. By inhibiting their function, the drug thereby inhibits normal cell division.
TargetKindPharmacological actionActionsOrganismUniProt ID
DNA gyrase subunit AProteinyes
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)P43700 details
DNA topoisomerase 4 subunit AProteinyes
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)P43702 details
DNA topoisomerase 2-alphaProteinunknown
inhibitor
HumanP11388 details
Related Articles
AbsorptionBioavailability of ofloxacin in the tablet formulation is approximately 98%
Volume of distributionNot Available
Protein binding32%
Metabolism

Hepatic

Route of eliminationElimination is mainly by renal excretion. Between 65% and 80% of an administered oral dose of ofloxacin is excreted unchanged via the kidneys within 48 hours of dosing. Four to eight percent of an ofloxacin dose is excreted in the feces. This indicates a small degree of biliary excretion of ofloxacin.
Half life9 hours
ClearanceNot Available
ToxicityLD50=5450 mg/kg (orally in mice)
Affected organisms
  • Enteric bacteria and other eubacteria
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Ofloxacin.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Ofloxacin.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Ofloxacin.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Ofloxacin.Experimental, Illicit
AcarboseOfloxacin may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AceclofenacAceclofenac may increase the neuroexcitatory activities of Ofloxacin.Approved
AcenocoumarolOfloxacin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneAcetovanillone may increase the neuroexcitatory activities of Ofloxacin.Investigational
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Ofloxacin.Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Ofloxacin.Approved, Vet Approved
AdapaleneAdapalene may increase the neuroexcitatory activities of Ofloxacin.Approved
AlbiglutideOfloxacin may increase the hypoglycemic activities of Albiglutide.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Ofloxacin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Ofloxacin.Experimental
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
AlogliptinOfloxacin may increase the hypoglycemic activities of Alogliptin.Approved
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmantadineAmantadine may increase the QTc-prolonging activities of Ofloxacin.Approved
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Ofloxacin.Experimental
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Ofloxacin.Approved
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Ofloxacin.Approved
AmiodaroneOfloxacin may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Ofloxacin.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Ofloxacin.Approved
AnagrelideOfloxacin may increase the QTc-prolonging activities of Anagrelide.Approved
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Ofloxacin.Investigational
AnisodamineAnisodamine may increase the neuroexcitatory activities of Ofloxacin.Investigational
AntipyrineAntipyrine may increase the neuroexcitatory activities of Ofloxacin.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Ofloxacin.Investigational
ApomorphineApomorphine may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
ApremilastApremilast may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
Arsenic trioxideOfloxacin may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherOfloxacin may increase the QTc-prolonging activities of Artemether.Approved
AsenapineOfloxacin may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirAtazanavir may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Ofloxacin.Approved
AzapropazoneAzapropazone may increase the neuroexcitatory activities of Ofloxacin.Withdrawn
AzelastineAzelastine may increase the neuroexcitatory activities of Ofloxacin.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Ofloxacin.Approved
BalsalazideBalsalazide may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Ofloxacin.Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Beclomethasone is combined with Ofloxacin.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Ofloxacin.Approved, Investigational
BedaquilineOfloxacin may increase the QTc-prolonging activities of Bedaquiline.Approved
BenoxaprofenBenoxaprofen may increase the neuroexcitatory activities of Ofloxacin.Withdrawn
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Ofloxacin.Approved, Vet Approved
Betulinic AcidBetulinic Acid may increase the neuroexcitatory activities of Ofloxacin.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Ofloxacin.Approved, Investigational
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
BromfenacBromfenac may increase the neuroexcitatory activities of Ofloxacin.Approved
BromocriptineOfloxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BucillamineBucillamine may increase the neuroexcitatory activities of Ofloxacin.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Ofloxacin.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Ofloxacin.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ofloxacin.Approved
CalciumCalcium can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Nutraceutical
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium ChlorideCalcium Chloride can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium citrateCalcium citrate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium glubionateCalcium glubionate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium GluceptateCalcium Gluceptate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CanagliflozinOfloxacin may increase the hypoglycemic activities of Canagliflozin.Approved
CarprofenCarprofen may increase the neuroexcitatory activities of Ofloxacin.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the neuroexcitatory activities of Ofloxacin.Experimental
CelecoxibCelecoxib may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
CeritinibOfloxacin may increase the QTc-prolonging activities of Ceritinib.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Ofloxacin.Approved, Vet Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Ofloxacin.Approved, Vet Approved
ChlorpropamideOfloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Ofloxacin.Approved, Investigational
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
CisaprideOfloxacin may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramOfloxacin may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinOfloxacin may increase the QTc-prolonging activities of Clarithromycin.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Ofloxacin.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Ofloxacin.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Ofloxacin.Approved
ClomipramineClomipramine may increase the QTc-prolonging activities of Ofloxacin.Approved, Vet Approved
ClonixinClonixin may increase the neuroexcitatory activities of Ofloxacin.Approved
ClozapineClozapine may increase the QTc-prolonging activities of Ofloxacin.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Ofloxacin.Approved
CrizotinibOfloxacin may increase the QTc-prolonging activities of Crizotinib.Approved
CurcuminCurcumin may increase the neuroexcitatory activities of Ofloxacin.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Ofloxacin.Approved, Investigational
D-LimoneneD-Limonene may increase the neuroexcitatory activities of Ofloxacin.Investigational
DabrafenibDabrafenib may increase the QTc-prolonging activities of Ofloxacin.Approved
DapagliflozinOfloxacin may increase the hypoglycemic activities of Dapagliflozin.Approved
DasatinibDasatinib may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Ofloxacin.Approved
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Ofloxacin.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Ofloxacin.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Ofloxacin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Ofloxacin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Ofloxacin.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Ofloxacin.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Ofloxacin.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Ofloxacin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Ofloxacin.Vet Approved
DiclofenacDiclofenac may increase the neuroexcitatory activities of Ofloxacin.Approved, Vet Approved
DicoumarolOfloxacin may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Ofloxacin.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Ofloxacin.Approved
DiflunisalDiflunisal may increase the neuroexcitatory activities of Ofloxacin.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Ofloxacin.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Ofloxacin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Ofloxacin.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Ofloxacin.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Ofloxacin.Approved
DisopyramideOfloxacin may increase the QTc-prolonging activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ofloxacin.Approved, Investigational
DofetilideOfloxacin may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Ofloxacin.Approved
DomperidoneOfloxacin may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Ofloxacin.Approved
DronedaroneOfloxacin may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Ofloxacin.Approved, Vet Approved
DroxicamDroxicam may increase the neuroexcitatory activities of Ofloxacin.Approved
DulaglutideOfloxacin may increase the hypoglycemic activities of Dulaglutide.Approved
DuvelisibDuvelisib may increase the neuroexcitatory activities of Ofloxacin.Investigational
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Ofloxacin.Approved
E6201E6201 may increase the neuroexcitatory activities of Ofloxacin.Investigational
EbselenEbselen may increase the neuroexcitatory activities of Ofloxacin.Investigational
EliglustatOfloxacin may increase the QTc-prolonging activities of Eliglustat.Approved
EmpagliflozinOfloxacin may increase the hypoglycemic activities of Empagliflozin.Approved
EpirizoleEpirizole may increase the neuroexcitatory activities of Ofloxacin.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Ofloxacin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Ofloxacin.Approved
EribulinEribulin may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Ofloxacin.Approved, Vet Approved
EscitalopramOfloxacin may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Ofloxacin.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Ofloxacin.Approved
EtanerceptEtanercept may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
Ethyl biscoumacetateOfloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the neuroexcitatory activities of Ofloxacin.Approved
EtoricoxibEtoricoxib may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the neuroexcitatory activities of Ofloxacin.Approved
ExenatideOfloxacin may increase the hypoglycemic activities of Exenatide.Approved, Investigational
exisulindexisulind may increase the neuroexcitatory activities of Ofloxacin.Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Ofloxacin.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Ofloxacin.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Ofloxacin.Approved
FenbufenFenbufen may increase the neuroexcitatory activities of Ofloxacin.Approved
FenoprofenFenoprofen may increase the neuroexcitatory activities of Ofloxacin.Approved
Ferric CarboxymaltoseThe serum concentration of Ofloxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
Ferric CitrateThe serum concentration of Ofloxacin can be decreased when it is combined with Ferric Citrate.Approved
Ferric pyrophosphateThe serum concentration of Ofloxacin can be decreased when it is combined with Ferric pyrophosphate.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
FlecainideOfloxacin may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FloctafenineFloctafenine may increase the neuroexcitatory activities of Ofloxacin.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Ofloxacin.Investigational
FluconazoleFluconazole may increase the QTc-prolonging activities of Ofloxacin.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Ofloxacin.Approved
FluindioneOfloxacin may increase the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Ofloxacin.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Ofloxacin.Approved, Investigational
FlunixinFlunixin may increase the neuroexcitatory activities of Ofloxacin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Ofloxacin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Ofloxacin.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Ofloxacin.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Ofloxacin.Approved
FluoxetineOfloxacin may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolOfloxacin may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Ofloxacin.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Ofloxacin.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Ofloxacin.Approved
FlurbiprofenFlurbiprofen may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Ofloxacin.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Ofloxacin.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Ofloxacin.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
FoscarnetFoscarnet may increase the QTc-prolonging activities of Ofloxacin.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Ofloxacin.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Ofloxacin.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
GliclazideOfloxacin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideOfloxacin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideOfloxacin may increase the hypoglycemic activities of Glipizide.Approved
GlyburideOfloxacin may increase the hypoglycemic activities of Glyburide.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Ofloxacin.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
HaloperidolHaloperidol may increase the QTc-prolonging activities of Ofloxacin.Approved
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Ofloxacin.Investigational
HigenamineHigenamine may increase the neuroexcitatory activities of Ofloxacin.Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Ofloxacin.Approved
HMPL-004HMPL-004 may increase the neuroexcitatory activities of Ofloxacin.Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Ofloxacin.Approved, Vet Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Ofloxacin.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
IbuprofenIbuprofen may increase the neuroexcitatory activities of Ofloxacin.Approved
IbuproxamIbuproxam may increase the neuroexcitatory activities of Ofloxacin.Withdrawn
IbutilideOfloxacin may increase the QTc-prolonging activities of Ibutilide.Approved
IcatibantIcatibant may increase the neuroexcitatory activities of Ofloxacin.Approved
IloperidoneOfloxacin may increase the QTc-prolonging activities of Iloperidone.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Ofloxacin.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Ofloxacin.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Ofloxacin.Approved
IndomethacinIndomethacin may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
IndoprofenIndoprofen may increase the neuroexcitatory activities of Ofloxacin.Withdrawn
Insulin AspartOfloxacin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirOfloxacin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineOfloxacin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineOfloxacin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanOfloxacin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproOfloxacin may increase the hypoglycemic activities of Insulin Lispro.Approved
IronThe serum concentration of Ofloxacin can be decreased when it is combined with Iron.Approved
Iron DextranThe serum concentration of Ofloxacin can be decreased when it is combined with Iron Dextran.Approved, Vet Approved
Iron saccharateThe serum concentration of Ofloxacin can be decreased when it is combined with Iron saccharate.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Ofloxacin.Approved, Vet Approved
IsoxicamIsoxicam may increase the neuroexcitatory activities of Ofloxacin.Withdrawn
IsradipineIsradipine may increase the QTc-prolonging activities of Ofloxacin.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Ofloxacin.Investigational
ItraconazoleItraconazole may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Ofloxacin.Approved
KebuzoneKebuzone may increase the neuroexcitatory activities of Ofloxacin.Experimental
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
KetoprofenKetoprofen may increase the neuroexcitatory activities of Ofloxacin.Approved, Vet Approved
KetorolacKetorolac may increase the neuroexcitatory activities of Ofloxacin.Approved
LanreotideOfloxacin may increase the hypoglycemic activities of Lanreotide.Approved
Lanthanum carbonateThe serum concentration of Ofloxacin can be decreased when it is combined with Lanthanum carbonate.Approved
LapatinibLapatinib may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
LeflunomideLeflunomide may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
LenvatinibOfloxacin may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
LiraglutideOfloxacin may increase the hypoglycemic activities of Liraglutide.Approved
LisofyllineLisofylline may increase the neuroexcitatory activities of Ofloxacin.Investigational
LithiumLithium may increase the QTc-prolonging activities of Ofloxacin.Approved
LopinavirOfloxacin may increase the QTc-prolonging activities of Lopinavir.Approved
LornoxicamLornoxicam may increase the neuroexcitatory activities of Ofloxacin.Approved
LoxoprofenLoxoprofen may increase the neuroexcitatory activities of Ofloxacin.Approved
LumefantrineOfloxacin may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibLumiracoxib may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium salicylateThe serum concentration of Ofloxacin can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium SulfateThe serum concentration of Ofloxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MaprotilineMaprotiline may increase the QTc-prolonging activities of Ofloxacin.Approved
MasoprocolMasoprocol may increase the neuroexcitatory activities of Ofloxacin.Approved
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Ofloxacin.Investigational
MecaserminOfloxacin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the neuroexcitatory activities of Ofloxacin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Ofloxacin.Approved
Mefenamic acidMefenamic acid may increase the neuroexcitatory activities of Ofloxacin.Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Ofloxacin.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Ofloxacin.Vet Approved
MeloxicamMeloxicam may increase the neuroexcitatory activities of Ofloxacin.Approved, Vet Approved
MesalazineMesalazine may increase the neuroexcitatory activities of Ofloxacin.Approved
MetamizoleMetamizole may increase the neuroexcitatory activities of Ofloxacin.Withdrawn
MetforminOfloxacin may increase the hypoglycemic activities of Metformin.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Ofloxacin.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Ofloxacin.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Ofloxacin.Approved, Vet Approved
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Ofloxacin.Approved
MifepristoneMifepristone may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
MiglitolOfloxacin may increase the hypoglycemic activities of Miglitol.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Ofloxacin.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Ofloxacin.Approved
MizoribineMizoribine may increase the neuroexcitatory activities of Ofloxacin.Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Ofloxacin.Approved
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Ofloxacin.Approved, Vet Approved
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Ofloxacin.Approved
NabumetoneNabumetone may increase the neuroexcitatory activities of Ofloxacin.Approved
NafamostatNafamostat may increase the neuroexcitatory activities of Ofloxacin.Investigational
NaftifineNaftifine may increase the neuroexcitatory activities of Ofloxacin.Approved
NaproxenNaproxen may increase the neuroexcitatory activities of Ofloxacin.Approved, Vet Approved
NateglinideOfloxacin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Ofloxacin.Investigational
NCX 4016NCX 4016 may increase the neuroexcitatory activities of Ofloxacin.Investigational
NelfinavirNelfinavir may increase the QTc-prolonging activities of Ofloxacin.Approved
NepafenacNepafenac may increase the neuroexcitatory activities of Ofloxacin.Approved
NicardipineNicardipine may increase the QTc-prolonging activities of Ofloxacin.Approved
Niflumic AcidNiflumic Acid may increase the neuroexcitatory activities of Ofloxacin.Approved
NilotinibOfloxacin may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NimesulideNimesulide may increase the neuroexcitatory activities of Ofloxacin.Approved, Withdrawn
NitroaspirinNitroaspirin may increase the neuroexcitatory activities of Ofloxacin.Investigational
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Ofloxacin.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Ofloxacin.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
OlanzapineOlanzapine may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
Oleoyl estroneThe risk or severity of adverse effects can be increased when Oleoyl estrone is combined with Ofloxacin.Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Ofloxacin.Approved
OlopatadineOlopatadine may increase the neuroexcitatory activities of Ofloxacin.Approved
OlsalazineOlsalazine may increase the neuroexcitatory activities of Ofloxacin.Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Ofloxacin.Approved
OrgoteinOrgotein may increase the neuroexcitatory activities of Ofloxacin.Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Ofloxacin.Approved
OxaprozinOxaprozin may increase the neuroexcitatory activities of Ofloxacin.Approved
OxyphenbutazoneOxyphenbutazone may increase the neuroexcitatory activities of Ofloxacin.Withdrawn
OxytocinOxytocin may increase the QTc-prolonging activities of Ofloxacin.Approved, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ofloxacin.Approved, Vet Approved
PaliperidoneOfloxacin may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatOfloxacin may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Ofloxacin.Approved
ParecoxibParecoxib may increase the neuroexcitatory activities of Ofloxacin.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Ofloxacin.Approved
PazopanibOfloxacin may increase the QTc-prolonging activities of Pazopanib.Approved
PentamidinePentamidine may increase the QTc-prolonging activities of Ofloxacin.Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Ofloxacin.Approved
PhenindioneOfloxacin may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonOfloxacin may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazonePhenylbutazone may increase the neuroexcitatory activities of Ofloxacin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ofloxacin.Approved
PimecrolimusPimecrolimus may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
PimozideOfloxacin may increase the QTc-prolonging activities of Pimozide.Approved
PioglitazoneOfloxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirfenidonePirfenidone may increase the neuroexcitatory activities of Ofloxacin.Investigational
PiroxicamPiroxicam may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
PosaconazolePosaconazole may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational, Vet Approved
PramlintideOfloxacin may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Ofloxacin.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Ofloxacin.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Ofloxacin.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Ofloxacin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Ofloxacin.Experimental
PrimaquinePrimaquine may increase the QTc-prolonging activities of Ofloxacin.Approved
ProbenecidThe serum concentration of Ofloxacin can be increased when it is combined with Probenecid.Approved
ProcainamideOfloxacin may increase the QTc-prolonging activities of Procainamide.Approved
PromazinePromazine may increase the QTc-prolonging activities of Ofloxacin.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Ofloxacin.Approved
PropacetamolPropacetamol may increase the neuroexcitatory activities of Ofloxacin.Approved
PropafenoneOfloxacin may increase the QTc-prolonging activities of Propafenone.Approved
PropofolPropofol may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational, Vet Approved
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Ofloxacin.Approved
PTC299PTC299 may increase the neuroexcitatory activities of Ofloxacin.Investigational
QuetiapineOfloxacin may increase the QTc-prolonging activities of Quetiapine.Approved
QuinaprilThe serum concentration of Ofloxacin can be decreased when it is combined with Quinapril.Approved, Investigational
QuinidineOfloxacin may increase the QTc-prolonging activities of Quinidine.Approved
QuinineOfloxacin may increase the QTc-prolonging activities of Quinine.Approved
RanolazineRanolazine may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
RepaglinideOfloxacin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ResveratrolResveratrol may increase the neuroexcitatory activities of Ofloxacin.Experimental, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Ofloxacin.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Ofloxacin.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
RitonavirRitonavir may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
RofecoxibRofecoxib may increase the neuroexcitatory activities of Ofloxacin.Investigational, Withdrawn
RosiglitazoneOfloxacin may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Ofloxacin.Approved, Vet Approved
SalicylamideSalicylamide may increase the neuroexcitatory activities of Ofloxacin.Approved
Salicylic acidSalicylic acid may increase the neuroexcitatory activities of Ofloxacin.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Ofloxacin.Approved
SalsalateSalsalate may increase the neuroexcitatory activities of Ofloxacin.Approved
SaquinavirOfloxacin may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SaxagliptinOfloxacin may increase the hypoglycemic activities of Saxagliptin.Approved
SeratrodastSeratrodast may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
SertralineSertraline may increase the QTc-prolonging activities of Ofloxacin.Approved
SevelamerSevelamer can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Ofloxacin.Approved, Vet Approved
SitagliptinOfloxacin may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SolifenacinSolifenacin may increase the QTc-prolonging activities of Ofloxacin.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
SotalolOfloxacin may increase the QTc-prolonging activities of Sotalol.Approved
SRT501SRT501 may increase the neuroexcitatory activities of Ofloxacin.Investigational
Strontium ranelateThe serum concentration of Ofloxacin can be decreased when it is combined with Strontium ranelate.Approved
SucralfateThe serum concentration of Ofloxacin can be decreased when it is combined with Sucralfate.Approved
SulfadiazineOfloxacin may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Ofloxacin.Approved
SulfasalazineSulfasalazine may increase the neuroexcitatory activities of Ofloxacin.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Ofloxacin.Approved, Vet Approved
SulindacSulindac may increase the neuroexcitatory activities of Ofloxacin.Approved
SunitinibSunitinib may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
SuprofenSuprofen may increase the neuroexcitatory activities of Ofloxacin.Approved, Withdrawn
TamoxifenTamoxifen may increase the QTc-prolonging activities of Ofloxacin.Approved
TelavancinOfloxacin may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Ofloxacin.Approved
TenoxicamTenoxicam may increase the neuroexcitatory activities of Ofloxacin.Approved
TepoxalinTepoxalin may increase the neuroexcitatory activities of Ofloxacin.Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Ofloxacin.Approved
TeriflunomideTeriflunomide may increase the neuroexcitatory activities of Ofloxacin.Approved
TetrabenazineOfloxacin may increase the QTc-prolonging activities of Tetrabenazine.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Ofloxacin.Approved
ThioridazineOfloxacin may increase the QTc-prolonging activities of Thioridazine.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Ofloxacin.Approved
Tiaprofenic acidTiaprofenic acid may increase the neuroexcitatory activities of Ofloxacin.Approved
TinoridineTinoridine may increase the neuroexcitatory activities of Ofloxacin.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Ofloxacin.Approved
TizanidineTizanidine may increase the QTc-prolonging activities of Ofloxacin.Approved
TolazamideOfloxacin may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideOfloxacin may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may increase the neuroexcitatory activities of Ofloxacin.Approved
TolmetinTolmetin may increase the neuroexcitatory activities of Ofloxacin.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
ToremifeneOfloxacin may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TranilastTranilast may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Ofloxacin.Approved, Investigational
TrazodoneTrazodone may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Ofloxacin.Approved, Vet Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Ofloxacin.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Ofloxacin.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Ofloxacin.Approved, Vet Approved
Trisalicylate-cholineTrisalicylate-choline may increase the neuroexcitatory activities of Ofloxacin.Approved
ValdecoxibValdecoxib may increase the neuroexcitatory activities of Ofloxacin.Investigational, Withdrawn
VandetanibOfloxacin may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Ofloxacin.Approved
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Ofloxacin.Approved, Investigational
VemurafenibOfloxacin may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Ofloxacin.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Ofloxacin.Approved
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
WarfarinOfloxacin may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenZaltoprofen may increase the neuroexcitatory activities of Ofloxacin.Approved
ZileutonZileuton may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational, Withdrawn
ZiprasidoneOfloxacin may increase the QTc-prolonging activities of Ziprasidone.Approved
ZomepiracZomepirac may increase the neuroexcitatory activities of Ofloxacin.Withdrawn
ZuclopenthixolOfloxacin may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid high doses of caffeine.
  • Take without regard to meals.
References
Synthesis Reference

DrugSyn.org

US4382892
General ReferencesNot Available
External Links
ATC CodesS02AA16J01MA01J01RA09S01AE01
AHFS Codes
  • 08:12.18
  • 52:04.04
PDB EntriesNot Available
FDA labelDownload (198 KB)
MSDSDownload (73.9 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9545
Blood Brain Barrier-0.9659
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.7862
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.7489
CYP450 2C9 substrateNon-substrate0.8468
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6386
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9268
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7726
Ames testAMES toxic0.7844
CarcinogenicityNon-carcinogens0.9033
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.1639 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8402
hERG inhibition (predictor II)Non-inhibitor0.866
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
LiquidIntravenous20 mg
TabletOral200 mg
TabletOral300 mg
TabletOral400 mg
SolutionOphthalmic0.3 %
SolutionAuricular (otic)3 mg/mL
SolutionOphthalmic3 mg/mL
Solution / dropsAuricular (otic)3 mg/mL
Solution / dropsOphthalmic3 mg/mL
Tablet, coatedOral200 mg/1
Tablet, coatedOral300 mg/1
Tablet, coatedOral400 mg/1
Tablet, film coatedOral200 mg/1
Tablet, film coatedOral300 mg/1
Tablet, film coatedOral400 mg/1
Prices
Unit descriptionCostUnit
Floxin Otic 0.3% Solution 10ml Bottle142.91USD bottle
Ofloxacin 10ml Otic (ear) Solution132.19USD bottle
Ofloxacin 10ml. Ophthalmic (eye) Solution87.6USD bottle
Floxin Otic 0.3% Solution 5ml Bottle86.49USD bottle
Ofloxacin 5ml Otic (ear) Solution77.21USD bottle
Ofloxacin 5ml. Ophthalmic (eye) Solution43.86USD bottle
Ocuflox 0.3% eye drops11.35USD ml
Floxin 400 mg tablet9.55USD tablet
Ofloxacin 0.3% eye drops8.08USD ml
Floxin 200 mg tablet6.6USD tablet
Ofloxacin 400 mg tablet6.12USD tablet
Ofloxacin 300 mg tablet5.81USD tablet
Floxin 300 mg tablet5.61USD tablet
Ofloxacin 200 mg tablet4.88USD tablet
Floxin otic singles4.28USD each
Ocuflox 0.3 % Solution2.75USD ml
Apo-Ofloxacin 0.3 % Solution1.04USD ml
Pms-Ofloxacin 0.3 % Solution1.04USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5401741 No1995-03-272012-03-27Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point254 dec °CPhysProp
water solubility28.3 mg/mLNot Available
logP-0.39HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility1.44 mg/mLALOGPS
logP-0.02ALOGPS
logP0.65ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)5.45ChemAxon
pKa (Strongest Basic)6.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area73.32 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity94.94 m3·mol-1ChemAxon
Polarizability36.69 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassQuinolines and derivatives
Sub ClassQuinoline carboxylic acids
Direct ParentQuinoline carboxylic acids
Alternative Parents
Substituents
  • Quinoline-3-carboxylic acid
  • N-arylpiperazine
  • Fluoroquinolone
  • Hydroxyquinoline
  • Dihydroquinolone
  • Aminoquinoline
  • Dihydroquinoline
  • Benzoxazine
  • Pyridine carboxylic acid or derivatives
  • Pyridine carboxylic acid
  • Dialkylarylamine
  • N-alkylpiperazine
  • N-methylpiperazine
  • Fluorobenzene
  • Alkyl aryl ether
  • Benzenoid
  • Pyridine
  • Piperazine
  • 1,4-diazinane
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • Vinylogous amide
  • Tertiary aliphatic amine
  • Tertiary amine
  • Oxacycle
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
yes
Actions
inhibitor
General Function:
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function:
DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings.
Gene Name:
gyrA
Uniprot ID:
P43700
Molecular Weight:
97817.145 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Schmitz FJ, Hofmann B, Hansen B, Scheuring S, Luckefahr M, Klootwijk M, Verhoef J, Fluit A, Heinz HP, Kohrer K, Jones ME: Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob Chemother. 1998 Apr;41(4):481-4. [PubMed:9598779 ]
  4. Cambau E, Sougakoff W, Besson M, Truffot-Pernot C, Grosset J, Jarlier V: Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J Infect Dis. 1994 Nov;170(5):1351. [PubMed:7963747 ]
  5. Shi R, Zhang J, Li C, Kazumi Y, Sugawara I: Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing. J Clin Microbiol. 2006 Dec;44(12):4566-8. Epub 2006 Oct 11. [PubMed:17035499 ]
Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
yes
Actions
inhibitor
General Function:
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function:
Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.
Gene Name:
parC
Uniprot ID:
P43702
Molecular Weight:
83366.24 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Turner AK, Nair S, Wain J: The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets. J Antimicrob Chemother. 2006 Oct;58(4):733-40. Epub 2006 Aug 8. [PubMed:16895934 ]
  4. Chau TT, Campbell JI, Galindo CM, Van Minh Hoang N, Diep TS, Nga TT, Van Vinh Chau N, Tuan PQ, Page AL, Ochiai RL, Schultsz C, Wain J, Bhutta ZA, Parry CM, Bhattacharya SK, Dutta S, Agtini M, Dong B, Honghui Y, Anh DD, Canh do G, Naheed A, Albert MJ, Phetsouvanh R, Newton PN, Basnyat B, Arjyal A, La TT, Rang NN, Phuong le T, Van Be Bay P, von Seidlein L, Dougan G, Clemens JD, Vinh H, Hien TT, Chinh NT, Acosta CJ, Farrar J, Dolecek C: Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. Antimicrob Agents Chemother. 2007 Dec;51(12):4315-23. Epub 2007 Oct 1. [PubMed:17908946 ]
  5. Ishiguro F, Toho M, Yamazaki M, Matsuyuki S, Moriya K, Tanaka D, Isobe J, Kyota Y, Muraoka M: [Mutations of gyrA gene and parC gene in fluoroquinolone-resistant Escherichia coli isolates from sporadic diarrheal cases]. Kansenshogaku Zasshi. 2006 Sep;80(5):507-12. [PubMed:17073264 ]
  6. Drlica K, Zhao X: DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92. [PubMed:9293187 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Ubiquitin binding
Specific Function:
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segregation of daughter chromosomes. May play a role in regulating the period length of ARNTL/BMAL1 transcriptional oscillation (By similarity).
Gene Name:
TOP2A
Uniprot ID:
P11388
Molecular Weight:
174383.88 Da
References
  1. Divo AA, Sartorelli AC, Patton CL, Bia FJ: Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 1988 Aug;32(8):1182-6. [PubMed:2847647 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Also relative uptake activity ratio of carnitine to TEA is 11.3.
Gene Name:
SLC22A5
Uniprot ID:
O76082
Molecular Weight:
62751.08 Da
References
  1. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PubMed:10525100 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Terashi K, Oka M, Soda H, Fukuda M, Kawabata S, Nakatomi K, Shiozawa K, Nakamura T, Tsukamoto K, Noguchi Y, Suenaga M, Tei C, Kohno S: Interactions of ofloxacin and erythromycin with the multidrug resistance protein (MRP) in MRP-overexpressing human leukemia cells. Antimicrob Agents Chemother. 2000 Jun;44(6):1697-700. [PubMed:10817732 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Jariyawat S, Sekine T, Takeda M, Apiwattanakul N, Kanai Y, Sophasan S, Endou H: The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther. 1999 Aug;290(2):672-7. [PubMed:10411577 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Sasabe H, Tsuji A, Sugiyama Y: Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats. J Pharmacol Exp Ther. 1998 Mar;284(3):1033-9. [PubMed:9495864 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Relative uptake activity ratio of carnitine to TEA is 1.78. A key substrate of this transporter seems to be ergothioneine (ET).
Gene Name:
SLC22A4
Uniprot ID:
Q9H015
Molecular Weight:
62154.48 Da
References
  1. Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A: Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73. [PubMed:10215651 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23